Literature DB >> 33688985

18Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes.

Moozhan Nikpanah1, Anna K Paschall2, Mark A Ahlman1, Ali Cahid Civelek3, Faraz Farhadi1,4, S Mojdeh Mirmomen5, Xiaobai Li6, Babak Saboury1, Mark W Ball7, Maria J Merino8, Ramaprasad Srinivasan7, Elizabeth C Jones1, W Marston Linehan9, Ashkan A Malayeri10.   

Abstract

PURPOSE: To assess differences in FDG-PET/CT uptake among four subtypes of renal tumors: clear cell RCC (ccRCC), papillary type I and II RCC (pRCC), and oncocytoma.
METHODS: This retrospective study investigated 33 patients with 98 hereditary renal tumors. Lesions greater than 1 cm and patients with a timeframe of less than 18 months between preoperative imaging and surgery were considered. FDG-PET/CT images were independently reviewed by two nuclear medicine physicians, blinded to clinical information. Volumetric lesion SUVmean was measured and used to calculate a target-to-background ratio respective to liver (TBR). The Shrout-Fleiss intra-class correlation coefficient was used to assess reliability between readers. A linear mixed effects model, accounting for within-patient correlations, was used to compare TBR values of primary renal lesions with and without distant metastasis.
RESULTS: The time interval between imaging and surgery for all tumors had a median of 77 (Mean: 139; Range: 1-512) days. Intra-class reliability of mean TBR resulted in a mean κ score of 0.93, indicating strong agreement between the readers. The mixed model showed a significant difference in mean TBR among the subtypes (p < 0.0001). Pairwise comparison showed significant differences between pRCC type II and ccRCC (p < 0.0001), pRCC type II and pRCC type I (p = 0.0001), and pRCC type II and oncocytoma (p = 0.0016). Furthermore, a significant difference in FDG uptake was present between primary pRCC type II renal lesions with and without distant metastasis (p = 0.023).
CONCLUSION: pRCC type II lesions demonstrated significantly higher FDG activity than ccRCC, pRCC type I, or oncocytoma. These findings indicate that FDG may prove useful in studying the metabolic activity of renal neoplasms, identifying lesions of highest clinical concern, and ultimately optimizing active surveillance, and personalizing management plans.

Entities:  

Keywords:  18FDG-PET/CT; Hereditary Kidney Cancer Syndromes; Renal tumors; Subtype differentiation

Mesh:

Substances:

Year:  2021        PMID: 33688985      PMCID: PMC9389933          DOI: 10.1007/s00261-021-02999-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  37 in total

1.  Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.

Authors:  S Ramdave; G W Thomas; S U Berlangieri; D M Bolton; I Davis; H T Danguy; D Macgregor; A M Scott
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

Review 2.  Molecular imaging of cancer with positron emission tomography.

Authors:  Sanjiv Sam Gambhir
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 3.  Genetic predisposition to kidney cancer.

Authors:  Laura S Schmidt; W Marston Linehan
Journal:  Semin Oncol       Date:  2016-09-22       Impact factor: 4.929

Review 4.  Percutaneous ablation techniques for renal cell carcinoma: current status and future trends.

Authors:  D Filippiadis; G Mauri; P Marra; G Charalampopoulos; N Gennaro; F De Cobelli
Journal:  Int J Hyperthermia       Date:  2019-10       Impact factor: 3.914

Review 5.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

Review 6.  Correlating Preoperative Imaging with Histologic Subtypes of Renal Cell Carcinoma and Common Mimickers.

Authors:  Jennifer Gordetsky; Jessica Zarzour
Journal:  Curr Urol Rep       Date:  2016-07       Impact factor: 3.092

Review 7.  The genetic basis of cancer of the kidney.

Authors:  W Marston Linehan; McClellan M Walther; Berton Zbar
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

8.  Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.

Authors:  Reiko Nakajima; Koichiro Abe; Tsunenori Kondo; Kazunari Tanabe; Shuji Sakai
Journal:  Eur Radiol       Date:  2015-09-24       Impact factor: 5.315

9.  Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.

Authors:  Tomoya Mizuno; Takao Kamai; Hideyuki Abe; Setsu Sakamoto; Kazuhiro Kitajima; Daisaku Nishihara; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Masahiro Yashi; Yoshitatsu Fukabori; Yasushi Kaji; Ken-Ichiro Yoshida
Journal:  BMC Cancer       Date:  2015-03-10       Impact factor: 4.430

Review 10.  Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.

Authors:  Hsin-Yi Wang; Hueisch-Jy Ding; Jin-Hua Chen; Chih-Hao Chao; Yu-Yu Lu; Wan-Yu Lin; Chia-Hung Kao
Journal:  Cancer Imaging       Date:  2012-10-26       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.